SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
kuyng
Lv1
10 积分
2022-09-07 加入
最近求助
最近应助
互助留言
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
3天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
3天前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
6天前
已完结
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies
6天前
已完结
EGFR-mutated NSCLC: A roadmap to treatment sequences
7天前
已关闭
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
16天前
已完结
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
1个月前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
1个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
1个月前
已完结
没有进行任何应助
速度真快
3天前
其他渠道获得【积分已退回】
3天前
需要的是补充材料,谢谢
1个月前
需要的是补充文件
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论